All In Biotech

Drug Trial Radar · NCT00211016

Doripenem in the Treatment of Ventilator-Associated Pneumonia

A Multicenter, Randomized, Open-Label, Phase 3 Study of Doripenem Versus a Comparator Antibiotic in the Treatment of Ventilator-Associated Pneumonia

Last checked: Nov 20, 2026Latest source record: Jun 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 318 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

318

Actual

Start

Aug 2004

Primary completion

Not stated

Study completion Oct 2006

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Peninsula Pharmaceuticals, Inc.
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the clinical response rate of doripenem versus comparator in patients with ventilator-associated pneumonia (VAP).

Conditions

  • Pneumonia
  • Ventilators, Mechanical

Interventions

  • doripenemDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical response rate at the early follow-up visit.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.